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Background: The original AGREE (Appraisal of Guidelines for REsearch and Evaluation) Instrument was published in
2003, and its revision, the AGREE II, in 2009. Together, they filled an important gap in the guideline and quality of
care fields. Ten years later, the AGREE Enterprise reflects on a trajectory of projects and international collaboration that
have contributed to advancing the science and quality of practice guidelines and the uptake of AGREE/AGREE II.
Findings: The AGREE Enterprise has undertaken activities to improve the tool and to develop resources to support its
use. Since 2003, the uptake and adoption of AGREE by the international community has been swift and broad. A total of
33 language translations of the original AGREE Instrument and the current AGREE II are available and were initiated by
the international community. A recent scan of the published literature identified over 600 articles that referenced the
AGREE tools. The AGREE tools have been widely received and applied, with several organizations having incorporated
the AGREE as part of their formal practice guideline programs. Since its redevelopment in 2010, the AGREE Enterprise
website (www.agreetrust.org) continues to experience steady increases in visitors per month and currently has over
10,000 registered users.
Conclusions: The AGREE Enterprise has contributed to the advancements of guidelines through research activities and
international participation by scientific and user communities. As we enter a new decade, we look forward to ongoing
collaborations and contributing to further advancements to improve quality of care and health care systems.
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search and Evaluation) Enterprise celebrated its 10th
year since the publication of the original AGREE Instru-
ment [1]. Led by an evolving team of international re-
searchers and clinical practice guideline (CPG) developers
and users, the core goals of the AGREE program of re-
search have remained the same: to improve the quality of
patient care and health system performance through ad-
vances in the science and practice of CPGs by creating an
appraisal tool capable of differentiating among CPGs of
varying quality and to use the tool as a means to guide the
development and reporting of CPGs. Using the 1997
Cluzeau Instrument as a springboard for its development,
the original AGREE Instrument – a European-led and* Correspondence: mbrouwer@mcmaster.ca
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article, unless otherwise stated.international effort - was first published in 2003 after the
completion of a multi-year program of research by The
AGREE Collaboration. The original AGREE Instrument’s
uptake and adoption by the CPG community was swift
and filled an important gap in the CPG and quality of
care fields. The AGREE Instrument also contributed
to the establishment of the Guidelines International
Network (G-I-N) [2].
As with any appraisal instrument, there were oppor-
tunities to improve the usability, implementability and
measurement properties of the original AGREE. This
initiated another international effort, led by the AGREE
Next Steps Research Consortium, and resulted in a re-
vised tool, the AGREE II, published in 2009 [3]. The
AGREE II is comprised of the appraisal tool (23 items,
six domains, and a 7-point response scale) and User’s
Manual, which supports its application and guides users
on CPG development and reporting strategies. The work
of the Consortium also produced the Global Rating
Scale (GRS), a short and abridged version of the AGREEed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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and resources are limited [4].
The intent of the Consortium was not only to design a
better quality tool, but also to create strategies to facili-
tate its use and to continue to raise the overall quality
bar of the CPG enterprise internationally. To that end,
three key implementation strategies resulted to achieve
this goal. First, the AGREE Enterprise website [5] was
launched in 2010. In addition to making available the
original AGREE and the AGREE II instruments, their
translations, and profiles of AGREE-related research
projects, the website also included “My AGREE”, a plat-
form that would enable online completion and storage
of appraisals and the sharing of those appraisals among
users.
Second, was the development of the AGREE II training
tools, released in 2011. Through the AGREE A3 (Appli-
cation, Appropriateness, Action) program of research,
the team evaluated online tools via randomized-
controlled trial to determine which strategy was most ef-
fective at promoting knowledge of the AGREE II and in-
stilling confidence and satisfaction with its application
[6]. The two online training strategies, an avatar-led tu-
torial and a dynamic training experience, in addition to
the PDF version of AGREE II, are available through the
AGREE website [7]. These training tools have been re-
cently augmented by a comprehensive “Guidelines Re-
source Centre”, originally designed by the Capacity
Enhancement Program of the Canadian Partnership
Against Cancer [8]. It offers step-by-step training for
how to create and implement high quality CPGs and in-
cludes practical resources, templates, videos, and a sec-
tion outlining the AGREE II as a CPG development
framework.
Third, and most recently in 2013, through an inter-
national collaboration of users, “My AGREE PLUS” was
developed and launched. Building off the original “My
AGREE” version, the My AGREE PLUS platform offers
participants much greater functionality including the
capacity to facilitate online completion and coordination
of multiple-rater AGREE II assessments per CPG.
During the past 10 years, the AGREE instruments have
been widely received and applied. As of 2013, there have
been 33 translations of the original AGREE and the
AGREE II and another 10 translations of the AGREE II
are in development. We thank the international commu-
nity for initiating and undertaking these translations. A
recent initial scan of the published literature revealed
over 600 articles that have referenced the AGREE tools.
The AGREE II serves as a formal part of the CPG devel-
opment or evaluation protocols of many established
groups, including Cancer Care Ontario’s Program in
Evidence-based Care (PEBC, Canada) [9], the National
Institute for Health and Care Excellence (NICE, UK)[10], the World Health Organization (WHO) [11], and
most recently, the National Academy of Clinical Bio-
chemistry Laboratory Medicine (USA) [12]. The AGREE
II has been used to inform the development of recently
published CPG reporting standards including those de-
veloped by G-I-N [13] and the Institutes of Medicine’s
Trustworthy Guidelines initiative [14]. The AGREE En-
terprise website is visited and visited often – averaging
6,250 visitors per month. Further, there are over 10,000
“My AGREE PLUS” registered users (as of June 2014).
The AGREE II continues to be formally integrated in
many graduate-level training programs including the
Health Research Methodology graduate program at
McMaster University (Canada); Dalhousie University’s
Continuing Medical Education program (Canada); and
the Department of Family Medicine at the University of
Mississippi Medical Centre (USA). The topic of advan-
cing the science of CPG appraisal contributed signifi-
cantly to the training experiences of several international
research leaders during their doctoral studies, including
Francoise Cluzeau (UK: Cluzeau Instrument), Jako Burgers
(Netherlands: original AGREE Instrument), and Michelle
Kho (Canada: AGREE II instrument). Further, the AGREE
II continues to be used in varied research and quality
projects globally. For example, at the 2013 G-I-N
Conference, 94 plenary, short presentations, and poster
abstracts described using the instrument as part of, or
as the object of, its research or project agenda [15].
Where to next? Although the work of the AGREE En-
terprise is ongoing, its focus has changed direction. At
this time, no additional work is planned by the team to
modify or continue to refine the AGREE II, although the
team collaborates with other groups (e.g. the National
Guidelines Clearinghouse) to support the adaption of
the instrument to meet the needs of the users. There are
clearly items in which methodologies and gold standard
criteria for performance are required (e.g. editorial inde-
pendence); we encourage the research community to
take this on.
Our team is now focused on the development of a
complementary tool to the AGREE II, the AGREE REX
(Recommendation EXcellence). Whereas the AGREE II
targeted the methodological issues for developing the
whole guideline report, the team wishes to concentrate
its efforts on a program of research aimed at optimizing
the implementability, applicability, and quality of the
CPG recommendations. As a first step to this goal, the
team collaborated widely with other research groups to
create the GUIDE-M (GUideline Implementability for
Decision Excellence Model); a comprehensive evidence-
informed framework of intrinsic CPG factors associated
with the uptake of recommendations. In addition, the
GUIDE-M allows us to plot existing CPG tools and ad-
vancements to identify (i) where sufficient gains have
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be required and (ii) gaps where investment of research
efforts may be most beneficial. GUIDE-M is undergoing
its final consultation phase and will be publicly available
in 2014. The GUIDE-M will serve as the foundation
from which the AGREE-REX will be designed. The team
is also currently leading a new project to create a tool to
facilitate the appraisal, development and reporting of
health systems guidance.
Over the past 10 years the AGREE Enterprise has con-
tributed to the advancements of CPGs through its vari-
ous research activities and international participation by
the scientific and user communities. As we enter a new
decade, we look forward to ongoing and expansive col-
laborations and contributing to further advancements
that will be useful to improve quality of care and health
care systems.
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